ADAPY — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2025-08-13

• On July 27, 2025, we entered into an asset purchase agreement (the “Asset Purchase Agreement”) with USWM CT, LLC (“Purchaser”), a subsidiary of US WorldMeds Partners, LLC (together with Purchaser, “US WorldMeds”). Pursuant to the terms set forth in the Asset Purchase Agreement, we agreed to sell to …

• We have been focused on the commercialization of TECELRA for the treatment of advanced synovial sarcoma and for which we received FDA approval on August 1, 2024. Commercialization of TECELRA will now pass to US WorldMeds and we will work with them to ensure a smooth transition.

• NY-ESO-1 antigen. The development of lete-cel will now pass to US WorldMeds and we will work with them on the anticipated BLA filing.

• We anticipated filing a clinical trial authorization for a Phase 1 trial in head and neck cancer in collaboration with Galapagos during 2025. The conduct of the Phase 1 trial will now pass to US WorldMeds as part of the Transaction and we will work with them to ensure a smooth transition.

• On July 27, 2025, the Company entered into the Asset Purchase Agreement. Pursuant to the terms set forth in the Asset Purchase Agreement, Adaptimmune agreed to sell to Purchaser the assets and rights related to Adaptimmune’s TECELRA, letecel, afami-cel and uza-cel cell therapies, and Purchaser agree…

Text removed vs the prior filing · source: 10-Q · 2025-05-13

• We are currently in the process of evaluating strategic options for the Company.

• We are focused on the commercialization of TECELRA for the treatment of advanced synovial sarcoma and for which we received FDA approval on August 1, 2024. As of May 13, 2025, 28 Authorized Treatment Centers (“ATCs”) are available to initiate the treatment journey for our patients. During the first …

• *Afami-cel also being investigated in the pediatric basket trial SPEARHEAD-3.

• **Data cut-off March 1, 2024, primary efficacy analysis conducted on 64 patients treated with lete-cel protocol (commercial supply). Data presented at CTOS 2024 by Dr Sandra D’Angelo

• We anticipate filing a clinical trial authorization for a Phase 1 trial in head and neck cancer in collaboration with Galapagos during 2025. The trial will utilize ADP-5701, uza-cel manufactured using Galapagos’ innovative decentralized cell therapy manufacturing platform. Uza-cel has shown encourag…

Text added vs the prior filing · source: 10-Q · 2025-08-13

• On July 16, 2025, the Company entered into the Settlement Agreement with MD Anderson. As previously disclosed in the Company’s 2024 Annual Report and its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, MD Anderson served litigation in the District Court of Harris County …

• Solely to avoid the costs, risks and uncertainties inherent in litigation, the Company and MD Anderson entered into the Settlement Agreement. The Settlement Agreement provides for the release and dismissal of all claims relating to the Alliance Agreement, with dismissal being dependent on receipt of…

Text removed vs the prior filing · source: 10-Q · 2025-05-13

• On December 2, 2024, the University of Texas M.D. Anderson Cancer Center (“MD Anderson”) served litigation in the District Court of Harris County against Adaptimmune LLC (“Adaptimmune”). The litigation relates to a Strategic Alliance Agreement between MD Anderson and Adaptimmune dated September 23, …